INTRODUCTION: COVID-19 has several overlapping phases. Treatment has focused on the late stage of the disease in hospital. Yet, the continuation of the pandemic is by propagation of the disease in outpatients. The current public health strategy relies solely on vaccines to prevent disease.Areas Covered: We searched the major national registries, pubmed.org, and the preprint servers for all ongoing, completed and published trial results with subject numbers of 100 or more on, and used a targeted search to find announcements of unpublished trial results. As of 2/15/2021, we found 111 publications reporting findings in human studies on 14 classes of agents, and on 9 vaccines. There were 62 randomized controlled studies, the rest retrospective observational analyses. Only 21 publications dealt with outpatient care, the rest all in hospitalized patients. Remdesivir and convalescent plasma have emergency use authorization for hospitalized patients in the U.S.A. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. Monoclonal antibodies are authorized for outpatients, but the supply is inadequate to treat all at time of diagnosis. Favipiravir, ivermectin, and interferons are approved in certain countries.Expert Opinion: Worldwide vaccination is now underway. Vaccines and antibodies are highly antigen specific and new variants are appearing. There is a need for treatment of outpatients who contract the disease, in addition to mass immunization. We call on public health authorities to authorize treatments with known low risk and potential benefit for use in parallel with mass immunization.
The Time to Offer Treatments for COVID-19 / Ngo, Binh T; Marik, Paul; Kory, Pierre; Shapiro, Leland; Thomadsen, Raphael; Iglesias, Jose; Ditmore, Stephen; Rendell, Marc; Varon, Joseph; Dubé, Michael; Nanda, Neha; In, Gino; Arkfeld, Daniel; Chaudhary, Preet; Campese, Vito M; Hanna, Diana L; Sawcer, David E; Ehresmann, Glenn; Peng, David; Smogorewski, Miroslaw; Armstrong, April; Dasgupta, Rajkumar; Sattler, Fred; Brennan-Rieder, Denise; Mussini, Cristina; Mitja, Oriol; Soriano, Vicente; Peschanski, Nicolas; Hayem, Gilles; Confalonieri, Marco; Piccirillo, Maria Carmela; Lobo-Ferreira, Antonio; Bello Rivero, Iraldo; Turkia, Mika; Vingevoll, Eivind H; Griffin, Daniel; Hung, Ivan Fn. - In: EXPERT OPINION ON INVESTIGATIONAL DRUGS. - ISSN 1354-3784. - 30:5(2021), pp. 505-518. [10.1080/13543784.2021.1901883]
The Time to Offer Treatments for COVID-19
Mussini, Cristina;
2021
Abstract
INTRODUCTION: COVID-19 has several overlapping phases. Treatment has focused on the late stage of the disease in hospital. Yet, the continuation of the pandemic is by propagation of the disease in outpatients. The current public health strategy relies solely on vaccines to prevent disease.Areas Covered: We searched the major national registries, pubmed.org, and the preprint servers for all ongoing, completed and published trial results with subject numbers of 100 or more on, and used a targeted search to find announcements of unpublished trial results. As of 2/15/2021, we found 111 publications reporting findings in human studies on 14 classes of agents, and on 9 vaccines. There were 62 randomized controlled studies, the rest retrospective observational analyses. Only 21 publications dealt with outpatient care, the rest all in hospitalized patients. Remdesivir and convalescent plasma have emergency use authorization for hospitalized patients in the U.S.A. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. Monoclonal antibodies are authorized for outpatients, but the supply is inadequate to treat all at time of diagnosis. Favipiravir, ivermectin, and interferons are approved in certain countries.Expert Opinion: Worldwide vaccination is now underway. Vaccines and antibodies are highly antigen specific and new variants are appearing. There is a need for treatment of outpatients who contract the disease, in addition to mass immunization. We call on public health authorities to authorize treatments with known low risk and potential benefit for use in parallel with mass immunization.Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris